Special Issue

Anti-microbial Coating Innovations to Prevent Infectious Diseases

Message from the Guest Editors

The annual occurrence of healthcare-associated infections (HCAIs) caused by pathogens, particularly multidrug-resistant bacteria, has a significant impact on millions of patients worldwide. Antimicrobial-coating-based approaches, which have garnered substantial commercial investment and academic research endeavors, are widely acknowledged for their potential in mitigating microbial populations on surfaces within clinical settings. This Special Issue will encompass research that harnesses innovative agents or materials and strategies for the development of antimicrobial coatings aimed at preventing infectious diseases. Papers pertaining to the development of novel agents or materials for antimicrobial coatings and the significant prevention of infectious diseases, such as antimicrobial nanomaterials, herbal-medicine-derived antimicrobial agents, antimicrobial peptides, antibiotic adjuvants, and antimicrobial hydrogel dressings, are highly encouraged.

Guest Editors

Dr. Jinzhi Han

College of Biological Science and Technology, Fuzhou University, Fuzhou, China

Prof. Dr. Serena Riela

Department of Chemistry, University of Catania, Via Andrea Doria, 6, 95125 Catania, Italy

Deadline for manuscript submissions

closed (1 September 2024)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/197749

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI